February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a ...

GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma Solutions Inc., which has the exclusive rights to produce and sell the pharmacological stress agent Rapiscan (regadenoson) in territories outside the U.S., Canada and Mexico. GE Healthcare will help bring improved access to Rapiscan, offering an alternative screening method for patients who are unable to undergo traditional cardiac stress imaging procedures.

February 7, 2017 — Of the more than 700,000 Americans who suffer a heart attack each year, about a quarter go on to ...

At the 2016 Radiological Society of North America (RSNA) annual meeting, GE Healthcare unveiled Freelium, a magnet technology designed to use 1 percent of liquid helium compared to conventional magnetic resonance imaging (MRI) magnets. Instead of the average 2,000 liters of precious liquid helium, Freelium is designed to use only about 20 liters.

For over 20 years, stress echocardiography (SE) has been widely used to help clinicians diagnose ischemic heart disease, in which coronary arteries have narrowed, leading to restricted blood flow and damage to the heart. However, in recent years, stress echocardiography has also become an established method to assess a much wider array of complex heart conditions, such as heart failure and valvular heart disease. A new document, The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE), aims to establish guidance for how best to apply, perform and interpret SE for patients with a multitude of conditions.

Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to participate in the first-ever clinical study of combination adult stem cell therapy in cardiovascular medicine. Adult cell therapy has been studied in patients with heart disease with an excellent safety profile, though a combination of two cell types has not yet been evaluated in cardiovascular disease.